Skip to content
Parakho

Medicamen Biotech Ltd-$

NSE MEDICAMEQBSE 531146

Q1 FY27, unaudited

Revenue
₹47.90 Cr
Profit after tax
₹1.85 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations47.90+11.27%197.77
Other income0.86+83.20%3.11
Total income48.76+12.05%200.88
Employee benefit expense9.31+15.12%34.69
Finance costs0.83−28.14%3.50
Depreciation & amortisation1.79−0.80%7.22
Total expenses46.19+11.60%188.90
Profit before tax2.57+20.69%11.98
Tax expense0.73+36.80%2.19
Profit after tax1.85+15.35%9.80
Total comprehensive income1.85+15.35%9.80
Earnings per share
Earnings per share, basic₹1.36₹7.22
Earnings per share, diluted₹1.36₹7.22

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Medicamen Biotech Ltd-$ has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 15 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 18 Aug 2026.